Nevertheless, CSF1R remains a promising target for immunotherapy that can markedly improve the efficacy of T cell checkpoint immunotherapy and lead to tumor regression because CSF1/CSF1R inhibition decreases the number of TAMs and reduces immune suppression by reprogramming the remaining TAMs to support antigen presentation and enhance T cell activation within the TME [16,17,18]. This evidence concerns the gene CSF1R and neoplasm.